The Effect of Esmolol on Patients With Sepsis
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 120
- 主要终点
- REE
研究概览
简要总结
The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.
详细描述
Severe sepsis, septic shock, and their complications have become the major healthcare problem that affects millions of people each year, resulting in high mortality rates. Septic responses have an extremely complex chain of events including inflammatory and anti-inflammatory processes, humoral and cellular reactions, and cardiocirculatory abnormalities. Esmolol may have some potential in treating septic shock and sepsis. The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •sepsis patients
- •HR>100bpm 6h after admission
- •with CVC and ScvO2>65%
排除标准
- •age <18 years,
- •used β-blocker before,
- •cardiac dysrhythmias,
- •need for an inotropic agent,
- •valvular heart disease,
- •hemoglobin>6g/L
- •pregnancy.
研究组 & 干预措施
ES group
Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.
干预措施: Esmolol (Drug)
control group
Patients randomly assigned to the control group were treated with placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
REE
时间窗: Day 7 after enrollment
Resting energy expenditure
次要结局
- HR control rate(24 hours after enrollment)
- O2ER(Day 1/3/7 after enrollment)
- 28-day mortality rate(Day 28 after enrollment)
- Vasoactive drug administration dose(Day 1/3/7 after enrollment)
- Concentration of Lac(Day 1/3/7 after enrollment)